EDIT
NASDAQ
$2.88
Editas Medicine Inc (EDIT)
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $5.78 (+100.69%)
Market Cap
$349M
Free Cash Flow Yield
-40.38%
Beta (5Y)
2.15
Price Chart
Valuation
Market Cap$349M
P/S13.68
P/B123.59
Profitability
Total Revenue (TTM)$39M
Gross Profit (TTM)-$42M
EBITDA-$105M
Profit Margin-281.6%
Operating Margin-883%
EPS-$1.19
Financial Health
Debt-to-Equity1240.4%
Free Cash Flow Yield-40.38%
Growth & Risk
EPS 5Y CAGR-10.67%
Revenue 5Y CAGR-15.82%
FCF 5Y CAGR-4.79%
Beta (5Y)2.15
Sharpe Ratio0.47